In vivo hematopoietic reconstitution with EGF-responsive NSCs from human fetal brains.

One million EGF-responsive NSCs were injected directly into each human graft in SCID-hu mice. Graft cells were harvested 4 months after injection and subjected to flow cytometry for donor-derived hematopoietic cells. (A) Intrathymic T-cell development of EGF-generated primary spheres. Graft cells were analyzed for T-cell markers CD3, CD4, and CD8, and donor marker HLA-MA2.1. (B) B-cell and myeloid-cell differentiation of EGF-generated primary spheres in implanted human fetal bone fragments. Graft cells were analyzed by flow cytometry for B-cell marker CD19 (B) and myeloid marker CD33 (C), and a donor marker for EGF-generated primary spheres (HLA-MA2.1–positive). The percentage of B and myeloid cells expressing detectable levels of donor-specific class I antigen was recorded.